An immunocompetent mouse model of liposarcoma
Liposarcoma (LPS) is the most prevalent soft tissue sarcoma. The most common biological subtypes are well-differentiated (WDLPS), a low-grade disease that can evolve to high-grade dedifferentiated liposarcoma (DDLPS), with increased rates of recurrence and metastasis and low response rates to systemic therapies. Preclinical testing of immunotherapeutics for LPS has been held back by the lack of an immunocompetent mouse model. Here, we present an autochthonous immunocompetent LPS mouse model, ACPP, with targeted deletion of Trp53 and Pten in adipocytes to mimic signaling alterations observed in human LPS. Similar to humans, ACPP mice produce WDLPS, DDLPS, and tumors that exhibit both WD and DD components. Murine and human DDLPS tumors possess transcriptional similarities, including increased expression of oncogenes Cdk4 and Hmga2 and reduced expression of the tumor suppressor Cebpa; furthermore, both mouse and human DDLPS exhibit heterogenous T cell infiltration. Syngeneic cell lines derived from ACPP DDLPS reliably produce tumors following orthotopic implantation, each with distinct growth patterns, aggressiveness, and immune profiles. These unique models provide much needed tools to understand the complex immunobiology of LPS and greatly accelerate the pace of preclinical studies aimed at uncovering more effective new therapies for patients with this aggressive malignancy.